Soluble Receptor for Advanced Glycosylation End Products (sRAGE) ELISA, Antibody & Recombinant sRGAE is a novel biomarker for cardiovascular diseases Rat Soluble RAGE recombinant (catalog No.: 00112-03-100)had been used by Dr. Guo on her research paper: Caixia Guo, et al. A Soluble Receptor for Advanced Glycation End-Products Inhibits Hypoxia/Reoxygenation-Induced Apoptosis in Rat Cardiomyocytes via the Mitochondrial Pathway.Int J Mol Sci. 2012;13(9):11923-40. Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats Objective: Advanced glycation end-products (AGEs) exert inflammatory and oxidative stress insults to produce diabetic nephropathy mainly through the receptor for AGEs (RAGE). This study aimed to assess the effect of atorvastatin on diabetic nephropathy via soluble RAGE (sRAGE) and RAGE expressions in the rat kidney. Methods: Thirty-two male Sprague-Dawley rats were divided into four groups based on the presence or absence of streptozotocin-induced diabetes with or without atorvastatin treatment (10 mg/kg for 24 weeks). Serum sRAGE and glycated albumin (GA) levels were measured with enzyme-linked immunosorbent assay (ELISA) and improved bromocresol purple methods. Renal AGEs, RAGE, endogenous secretory RAGE (esRAGE), and sRAGE were determined with reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting. Results: Mesangial expansion and microalbuminuria were aggravated in diabetic rats, and improved with atorvastatin treatment. Serum sRAGE levels were lower in diabetic than in normal rats. After atorvastatin treatment, serum and renal sRAGE levels were up-regulated, while renal RAGE expression was decreased in diabetic rats, associated with a reduction in accumulation of AGEs, though renal esRAGE mRNA expression was not significantly increased. Conclusions: Atorvastatin exerted a beneficial effect on diabetic nephropathy with reduced AGE accumulation, down-regulating RAGE expression and up-regulating sRAGE in the kidney. Lu L., et al. J Zhejiang Univ Sci B. 2011 August; 12(8): 652–659.   Advanced Glycation End Products Accelerate Ischemia/Reperfusion Injury Through Receptor of Advanced End Product/Nitrative Thioredoxin Inactivation in Cardiac Microvascular Endothelial Cells The advanced glycation end products (AGEs) are associated with increased cardiac endothelial injury. However, no causative link has been established between increased AGEs and enhanced endothelial injury after ischemia/reperfusion. More importantly, the molecular mechanisms by which AGEs may increase endothelial injury remain unknown. Adult rat cardiac microvascular endothelial cells (CMECs) were isolated and incubated with AGE-modified bovine serum albumin (BSA) or BSA. After AGE-BSA or BSA preculture, CMECs were subjected to simulated ischemia (SI)/reperfusion (R). AGE-BSA increased SI/R injury as evidenced by enhanced lactate dehydrogenase release and caspase-3 activity. Moreover, AGE-BSA significantly increased SI/R-induced oxidative/nitrative stress in CMECs (as measured by increased inducible nitric oxide synthase expression, total nitric oxide production, superoxide generation, and peroxynitrite formation) and increased SI/R-induced nitrative inactivation of thioredoxin-1 (Trx-1), an essential cytoprotective molecule. Supplementation of EUK134 (peroxynitrite decomposition catalyst), human Trx-1, or soluble receptor of advanced end product (sRAGE) (a RAGE decoy) in AGE-BSA precultured cells attenuated SI/R-induced oxidative/nitrative stress, reduced SI/R-induced Trx-1 nitration, preserved Trx-1 activity, and reduced SI/R injury. Our results demonstrated that AGEs may increase SI/R-induced endothelial injury by increasing oxidative/nitrative injury and subsequent nitrative inactivation of Trx-1. Interventions blocking RAGE signaling or restoring Trx activity may be novel therapies to mitigate endothelial ischemia/reperfusion injury in the diabetic population. Antioxid. Redox Signal. 15, 1769–1778. Liu Y. et al. Antioxid. Redox Signal. 2011, 15, 1769–1778. Activation of the Receptor for Advanced Glycation End Products System in Women with Severe Preeclampsia Context: Activation of the receptor for advanced glycation end products (RAGE) mediates cellular injury. Soluble forms of RAGE [soluble RAGE (sRAGE), endogenous secretory (esRAGE)] bind RAGE ligands, thereby preventing downstream signaling and damage. Objectives: The objective of the study was to characterize the changes in maternal serum, amniotic fluid, and cord blood soluble receptor for advanced glycation end products (sRAGE) during physiological gestation and to provide insight into mechanisms responsible for RAGE activation in preeclampsia. Design and Settings: This was a cross-sectional study at a tertiary university hospital. Patients: We studied 135 women in the following groups: nonpregnant controls (n = 16), healthy pregnant controls (n = 68), pregnant women with chronic hypertension (n = 13), or pregnant women with severe preeclampsia (sPE; n = 38). Interventions and Main Outcome Measures: sRAGE and esRAGE levels were evaluated in vivo by ELISA in maternal serum, amniotic fluid, and cord blood and in vitro after stimulation of the amniochorion and placental explants with lipopolysaccharide or xanthine/xanthine oxidase. Placenta and amniochorion were immunostained for RAGE. Real-time quantitative PCR measured RAGE mRNA. Results: Pregnant women had significantly decreased serum sRAGE compared with nonpregnant subjects (P < 0.001). sPE women had higher serum and amniotic fluid sRAGE and esRAGE relative to those expected for gestational age (P < 0.001). Cord blood sRAGE remained unaffected by sPE. RAGE immunoreactivity and mRNA expression appeared elevated in the amniochorion of sPE women. Xanthine/xanthine oxidase (but not lipopolysaccharide) significantly up-regulated the release of sRAGE (P < 0.001) in the amniochorion explant system. Conclusions: Fetal membranes are a rich source of sRAGE. Elevated maternal serum and amniotic fluid sRAGE and esRAGE, paralleled by increased RAGE expression in the amniochorion, suggest activation of this system in sPE. Oliver EA et al. J Clin Endocrinol Metab. 2011 Feb 16. [Epub ahead of print] Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes Tam HL et al. Atherosclerosis. 2010 Mar;209(1):173-7. Epub 2009 Aug 21. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes Tam XH et al.Clin Sci (Lond). 2011 Jan;120(2):81-9.
		sRAGE (Human) Recombinant
		Code No.:00112-01-100 Size: 100ug Portein ID: Q15109 Gene ID: 177 MW : 39 KD Tag : 6x His Tag on N-Terminus Expressed : E. Coli More info: Data Sheet
		sRAGE (Rat) Recombinant
		Code No.:00112-03-100 Size: 100ug Portein ID: Q63495 Gene ID: Rn.9829 MW : 33.9 KD Tag : 6x His Tag on N-Terminus Expressed : E. Coli More info: Data Sheet
		Anti sRAGE (Human) IgG
		Code No.: A00112-02-100 Size: 100 ug Ab Type: Polyclonal IgG Purification: Protein A Host: Rabbit Antigen: sRAGE (Human) rec. Positive tissues: paraffin-embedded human kidney tissues Working Conc.: 2 ug/ml (Overnight incubation) Protocol: ABC More Info: PDF
		Haman sRAGE ELISA Kit Code No.: SK00112-02 Size: 96T Sensitivity: 20 pg/ml Standard rage: 78-5000 pg/ml Sample type: Serum, Plasma Sample Volume: 100 uL Intra CV: 6-8% Inter CV: 10-12% More Info: Protocol
		Rat/Mouse sRAGE ELISA Kit
		Code No.:SK00112-03 Size: 96T Standard Range: 0.026-400 ng/ml Linear range: 130-80000 pg/ml Sensitivity: 50 pg/ml Specificity: Mouse, Rat Sample type: serum or plasma Intra CV: 6-8% Inter CV: 10-12% More Info: Protocol
		Anti sRAGE (Rat) IgG
		Code No.: A00112-03-100 Size: 100 ug Ab Type: Polyclonal IgG Purification: Protein A Host: Rabbit Antigen: sRAGE (Rat), rec Positive tissues: paraffin-embedded rat and mouse kidney tissues Working Conc.: 2 ug/ml (Overnight incubation) Protocol: ABC More Info: PDF
		Anti esRAGE (Human) IgG
		Code No.: A00112-09-100 Size: 100 ug Ab Type: Polyclonal IgG Purification: Protein A Host: Rabbit Antigen: human esRAGE C-Terminal Rec Positive tissues: paraffin-embedded human and rat visceral adipose tissues Working Conc.: 2 ug/ml (Overnight incubation) Protocol: ABC More Info: PDF
		Anti esRAGE (Human) IgG
		Code No.: A00112-09-100 Size: 100 ug Ab Type: Polyclonal IgG Purification: Protein A Host: Rabbit Antigen: human esRAGE C-Terminal Rec Positive tissues: paraffin-embedded human and rat visceral adipose tissues Working Conc.: 2 ug/ml (Overnight incubation) Protocol: ABC More Info: PDF

Rabbit Anti esRAGE (Human) IgG (A00122-09-100) is available in stock that enables to detect esRAGE in serum. This antiobdy does not indicated crossreactivity with recombinat human sRAGE on ELISA.

Price/availability/specifications subject to change without notice. All products and services are for in vitro research use only. Not for use in or on humans or animals.